Latent membrane protein 2A (LMP2A), expressed in most Epstein-Barr virus (EBV)-associated malignancies, has been demonstrated to be responsible for the maintenance of latent infection and epithelial cell transformation. Besides, it could also act as the target for a CTL-based therapy for EBV-associated malignancies. In the present study, sequence variations of LMP2A in EBV-associated gastric carcinoma (EBVaGC) and healthy EBV carriers from Guangzhou, southern China, where nasopharyngeal carcinoma (NPC) is endemic, were investigated. Widespread sequence variations in the LMP2A gene were found, with no sequence identical to the B95.8 prototype. No consistent mutation was detected in all isolates. The immunoreceptor tyrosine-based activation motif (ITAM) and PY motifs in the amino terminus of LMP2A were strictly conserved, suggesting their important roles in virus infection; while 8 of the 17 identified CTL epitopes in the transmembrane region of LMP2A were affected by at least one point mutation, which may implicate that the effect of LMP2A polymorphisms should be considered when LMP2A-targeted immunotherapy is conducted. The polymorphisms of LMP2A in EBVaGC in gastric remnant carcinoma (GRC) were for the first time investigated in the world. The LMP2A sequence variations in EBVaGC in GRC were somewhat different from those in EBVaGC in conventional gastric carcinoma. The sequence variations of LMP2A in EBVaGC were similar to those in throat washing of healthy EBV carriers, indicating that these variations are due to geographic-associated polymorphisms rather than EBVaGC-associated mutations. This, to our best knowledge, is the first detailed investigation of LMP2A polymorphisms in EBVaGC in Guangzhou, southern China, where NPC is endemic.
References
[1]
Epstein MA, Achong BG, Barr YM (1964) Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet 1: 702–703.
[2]
Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757–768.
[3]
Akiba S, Koriyama C, Herrera-Goepfert R, Eizuru Y (2008) Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci 99: 195–201.
[4]
Lee JH, Kim SH, Han SH, An JS, Lee ES, et al. (2009) Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol 24: 354–365.
[5]
Uozaki H, Fukayama M (2008) Epstein-Barr virus and gastric carcinoma–viral carcinogenesis through epigenetic mechanisms. Int J Clin Exp Pathol 1: 198–216.
[6]
Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, et al. (1993) Epstein-Barr virus in gastric carcinoma. Am J Pathol 143: 1250–1254.
[7]
van Beek J, zur Hausen A, Klein Kranenbarg E, van de Velde CJ, Middeldorp JM, et al. (2004) EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 22: 664–670.
[8]
Murphy G, Pfeiffer R, Camargo MC, Rabkin CS (2009) Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 137: 824–833.
[9]
Thompson MP, Kurzrock R (2004) Epstein-Barr virus and cancer. Clin Cancer Res 10: 803–821.
[10]
zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, et al. (2000) Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res 60: 2745–2748.
[11]
Sugiura M, Imai S, Tokunaga M, Koizumi S, Uchizawa M, et al. (1996) Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Br J Cancer 74: 625–631.
[12]
Luo B, Wang Y, Wang XF, Liang H, Yan LP, et al. (2005) Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. World J Gastroenterol 11: 629–633.
[13]
Fruehling S, Longnecker R (1997) The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 235: 241–251.
[14]
Wang X, Liu X, Jia Y, Chao Y, Xing X, et al. (2010) Widespread sequence variation in the Epstein-Barr virus latent membrane protein 2A gene among northern Chinese isolates. J Gen Virol 91: 2564–2573.
[15]
Longnecker R (2000) Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv Cancer Res 79: 175–200.
[16]
Miller CL, Lee JH, Kieff E, Longnecker R (1994) An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A 91: 772–776.
[17]
Ikeda A, Caldwell RG, Longnecker R, Ikeda M (2003) Itchy, a Nedd4 ubiquitin ligase, downregulates latent membrane protein 2A activity in B-cell signaling. J Virol 77: 5529–5534.
[18]
Snyder MD, Pierce SK (2006) A mutation in Epstein-Barr virus LMP2A reveals a role for phospholipase D in B-Cell antigen receptor trafficking. Traffic 7: 993–1006.
[19]
Kong QL, Hu LJ, Cao JY, Huang YJ, Xu LH, et al. (2010) Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog 6: e1000940.
[20]
Scholle F, Bendt KM, Raab-Traub N (2000) Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 74: 10681–10689.
[21]
Fukuda M, Longnecker R (2004) Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol 78: 1697–1705.
[22]
Hino R, Uozaki H, Inoue Y, Shintani Y, Ushiku T, et al. (2008) Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A. Cancer Res 68: 1427–1435.
[23]
Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, et al. (2009) Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 69: 2766–2774.
[24]
Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB (1997) Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 158: 3325–3334.
[25]
Redchenko IV, Rickinson AB (1999) Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells. J Virol 73: 334–342.
[26]
Meij P, Leen A, Rickinson AB, Verkoeijen S, Vervoort MB, et al. (2002) Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer 99: 93–99.
[27]
Whitney BM, Chan AT, Rickinson AB, Lee SP, Lin CK, et al. (2002) Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. J Med Virol 67: 359–363.
[28]
Wang B, Yao K, Liu G, Xie F, Zhou F, et al. (2009) Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes. Cell Mol Immunol 6: 97–103.
[29]
Tanaka M, Kawaguchi Y, Yokofujita J, Takagi M, Eishi Y, et al. (1999) Sequence variations of Epstein-Barr virus LMP2A gene in gastric carcinoma in Japan. Virus Genes 19: 103–111.
[30]
Rickinson AB, Moss DJ (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15: 405–431.
[31]
Khanna R, Moss DJ, Burrows SR (1999) Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 170: 49–64.
[32]
Liu G, Yao K, Wang B, Chen Y, Zhou F, et al. (2009) Immunotherapy of Epstein-Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356–364 epitope fusion protein. Cell Mol Immunol 6: 423–431.
[33]
Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, et al. (2010) A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 116: 3695–3704.
[34]
International Agency for Research on Cancer WHO (1997) Epstein-Barr virus: summary of data reported and evaluation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; Volume 70. Lyon: IARC Press. pp. 255–262.
[35]
Lung ML, Lam WP, Sham J, Choy D, Yong-Sheng Z, et al. (1991) Detection and prevalence of the “f” variant of Epstein-Barr virus in southern China. Virology 185: 67–71.
[36]
Lung ML, Chang RS, Huang ML, Guo HY, Choy D, et al. (1990) Epstein-Barr virus genotypes associated with nasopharyngeal carcinoma in southern China. Virology 177: 44–53.
[37]
Chen JN, Ding YG, Feng ZY, Li HG, He D, et al. (2010) Association of distinctive Epstein-Barr virus variants with gastric carcinoma in Guangzhou, southern China. J Med Virol 82: 658–667.
[38]
Zeng MS, Li DJ, Liu QL, Song LB, Li MZ, et al. (2005) Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J Virol 79: 15323–15330.
[39]
Sinning C, Schaefer N, Standop J, Hirner A, Wolff M (2007) Gastric stump carcinoma - epidemiology and current concepts in pathogenesis and treatment. Eur J Surg Oncol 33: 133–139.
[40]
Safatle-Ribeiro AV, Ribeiro U Jr, Reynolds JC (1998) Gastric stump cancer: what is the risk? Dig Dis 16: 159–168.
[41]
Yamamoto N, Tokunaga M, Uemura Y, Tanaka S, Shirahama H, et al. (1994) Epstein-Barr virus and gastric remnant cancer. Cancer 74: 805–809.
[42]
Chang MS, Lee JH, Kim JP, Kim HS, Lee HS, et al. (2000) Microsatellite instability and Epstein-Barr virus infection in gastric remnant cancers. Pathol Int 50: 486–492.
[43]
Baas IO, van Rees BP, Musler A, Craanen ME, Tytgat GN, et al. (1998) Helicobacter pylori and Epstein-Barr virus infection and the p53 tumour suppressor pathway in gastric stump cancer compared with carcinoma in the non-operated stomach. J Clin Pathol 51: 662–666.
[44]
Chen JN, Jiang Y, Li HG, Ding YG, Fan XJ, et al. (2011) Epstein-Barr virus genome polymorphisms of Epstein-Barr virus-associated gastric carcinoma in gastric remnant carcinoma in Guangzhou, southern China, an endemic area of nasopharyngeal carcinoma. Virus Res 160: 191–199.
[45]
Lauren P (1965) The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand 64: 31–49.
[46]
Japanese Gastric Cancer Association (1998) Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1: 10–24.
[47]
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844–847.
[48]
Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, et al. (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6: 2743–2751.
[49]
Busson P, Edwards RH, Tursz T, Raab-Traub N (1995) Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. J Gen Virol 76(Pt 1): 139–145.
[50]
Franken M, Annis B, Ali AN, Wang F (1995) 5′ Coding and regulatory region sequence divergence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio. J Virol 69: 8011–8019.
[51]
Saiki Y, Ohtani H, Naito Y, Miyazawa M, Nagura H (1996) Immunophenotypic characterization of Epstein-Barr virus-associated gastric carcinoma: massive infiltration by proliferating CD8+ T-lymphocytes. Lab Invest 75: 67–76.
[52]
van Beek J, zur Hausen A, Snel SN, Berkhof J, Kranenbarg EK, et al. (2006) Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol 30: 59–65.
[53]
de Campos-Lima PO, Gavioli R, Zhang QJ, Wallace LE, Dolcetti R, et al. (1993) HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science 260: 98–100.
[54]
de Campos-Lima PO, Levitsky V, Brooks J, Lee SP, Hu LF, et al. (1994) T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med 179: 1297–1305.
